Previous close | 6.46 |
Open | 6.46 |
Bid | 5.70 |
Ask | 6.10 |
Strike | 7.50 |
Expiry date | 2024-10-18 |
Day's range | 6.46 - 6.46 |
Contract range | N/A |
Volume | |
Open interest | 2 |
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.